The iQ Group Global has entered into a material transfer agreement with Harvard University’s Wyss Institute to explore whether a proprietary technology developed at the Wyss Institute could be used to help provide a printable point-of-care SARS-CoV-2 antibody test for the COVID-19 disease that could produce results in real-time. Life Science Biosensor Diagnostics Pty Ltd […]

By Athena Kolivos, Chief Scientific Officer CRC and Farmaforce Imagine if you could be tested for SARS-CoV-2, the virus that causes the COVID-19 disease, at your local pharmacy, GP or in your own home, and receive results then and there. Point-of-Care Testing (PoCT) provides patients the ability to receive accurate and reliable testing results outside […]

Athena Kolivos, Chief Scientific Officer CRC & Farmaforce The vaccine discovery and development experience unfolding for COVID-19 serves as a timely reminder that researching, developing and commercialising therapies to prevent, treat or cure life-threatening diseases is an extensive process; one that is very different from bringing everyday products and commodities to the marketplace. Across the […]

Athena Kolivos, Chief Scientific Officer CRC and Farmaforce As the world continues to pull out all the stops to combat the COVID-19 pandemic and address the multiple challenges it poses to communities, governments and economies, the experience also serves as a strong reminder that life-threatening diseases need timely and effective solutions. Among these are many […]

With global healthcare under unprecedented pressure, innovation must accelerate like never before. Population increase, rising life expectancy, urbanisation and the spread of infectious diseases demand a new frontier for bioscience innovation to ensure the right medicines are developed when the world needs them most. The iQ Group Global is proud to share the launch of […]

The iQ Group Global is pleased to announce that Life Science Biosensor Diagnostics Pty Ltd (LSBD) has commenced engagement with the US Food and Drug Administration (FDA) for the approval pathway of the Saliva Glucose Biosensor. On May 1st, LSBD lodged a 513(g) submission, the first step to seeking regulatory approval for a device with […]

In our series ‘COVID-19 Explained’, experts from The iQ Group Global demystify frequently asked questions about the COVID-19 virus.   This week, CRC and Farmaforce Chief Scientific Officer Athena Kolivos explains the difference between a vaccine and an antibody test, and why both are important in the fight against the COVID-19 pandemic.  What is a vaccine and […]

The below article was produced by The University of Texas at Austin and republished here with permission. UNIVERSITY OF TEXAS AT AUSTIN – A drug candidate has been found in preclinical trials to stop tumor growth entirely, deliver more cancer-busting power than many commonly used chemotherapy drugs and do so with fewer toxic side effects […]

The iQ Group Global, an enterprise dedicated to developing early stage bioscience assets, announced that Dr. Jonathan Arambula will join The iQ Group Global as the Vice President of Research, OncoTEX Inc. OncoTEX Inc. is a member company of The iQ Group Global that specializes in the development of oncology drugs. Its novel anticancer drug platform, TEX […]

One of the world’s most renowned Chemists and co-founder of the biopharmaceutical company, Pharmacyclics, Professor Jonathan L. Sessler has been appointed as a Non-Executive Director to the board of OncoTEX Inc., it was announced today. OncoTEX Inc. is a member company of The iQ Group Global that specializes in the development of oncology drugs. Its […]